

United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, DC 20549
Attn.: Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance

**Re: Alzamed Neuro, Inc.
Amendment No. 1
Offering Statement on Form 1-A
Filed September 9, 2016
File No. 367-00052**

Dear Ms. Hayes:

Alzamed Neuro, Inc. (the "**Company**") hereby submits a response to certain comments made by the staff (the "**Staff**") of the Securities and Exchange Commission (the "**Commission**") in its letter dated October 17, 2016 (the "**Comment Letter**") relating to the Offering Statement on Form 1-A referenced above.

The Company's responses are numbered to correspond to the Staff's comments and are filed in conjunction with Amendment No. 2 to the Form 1-A (the "**Amendment No. 2**"). For your convenience, each of the Staff's comments contained in the Comment Letter has been restated below in its entirety, with the Company's response set forth immediately beneath such comment.

Directors, Executive Officers and Corporate Governance, page 49

Comment No. 1. We refer to your disclosure regarding the FINRA settlement with Mr. Ault on page 51. Please revise your disclosure to clarify, if true, that he did not make all of the restitution he was required to make to certain investors, and that such restitution was required to be paid within 120 days of the FINRA settlement, rather than merely before his reapplication for association with FINRA.

Response No. 1. We respectfully request your concurrence that the following language adequately addresses your comment:

"As part of that settlement, Mr. Ault agreed that he would make restitution to certain investors. Mr. Ault did not within the prescribed time period make a restitution payment to certain of the investors as he was unable to locate all of them, nor did he forward the undistributed restitution in the state where the investor was known to have resided, as directed by FINRA."

Pending a conversation with a member of the Staff, we understand that you are willing to accept the proposed language and have therefore inserted it into Amendment No. 2. We wish to thank you for your kind and expedient attention to this matter.

The Company does not presently plan to engage a member of FINRA in connection with its offering. While the Company is not presently seeking qualification of Amendment No. 1, the Company hereby acknowledges that:

- should the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking any action with respect to the filing;
 - the action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
 - the Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
-

Should you have any questions regarding the foregoing, please do not hesitate to contact the undersigned at (949) 346-5822 or our counsel Henry Nisser at (212) 930-9700.

Very truly yours,

/s/ Will Horne
Chief Financial Officer
